February 13, 2019
Takeda Pharmaceutical said on February 11 that its antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) earned an additional indication in Europe for its use in combination with adriamycin, vinblastine, and dacarbazine (AVD) in adult patients with previously untreated CD30-positive Stage IV...read more